We investigated pathogenic mutations relevant in dihydrolipoamide dehydrogenase (LADH; gene: Dld) deficiency, a severe human disease, to elucidate how they alter reactive oxygen species (ROS) generation and associated biophysical characteristics of LADH. Twelve known disease-causing mutants of human LADH have been expressed and purified to homogeneity from E. coli. Detailed biophysical and biochemical characterization of the mutants has been performed applying circular dichroism (CD) spectroscopy, nanospray mass spectrometry (MS), calibrated gel filtration and flavin adenine dinucleotide-content analysis. Functional analyses revealed that four of the pathogenic mutations significantly stimulated the ROS-generating activity of LADH and also increased its sensitivity to an acidic shift in pH. LADH activity was reduced by variable extents in the mutants exhibiting excessive ROS generation. It is remarkable that in the P453L mutant, enzyme activity was nearly completely lost with a ROS-forming activity becoming dominant, whereas the G194C mutation, common among Ashkenazi Jews, resulted in no alteration in LADH activity but a gain in the ROS-generating activity. There have been neither major conformational alterations nor monomerization of the functional homodimer of LADH associated with the higher ROS-generating capacity as measured by CD spectroscopy and size-exclusion chromatography combined with nano-spray MS, respectively. The excessive ROS generation of selected LADH mutants could be an important factor in the pathology and clinical presentation of human LADH deficiency and raises the possibility of an antioxidant therapy in the treatment of this condition.
INTRODUCTION
Alpha-ketoglutarate dehydrogenase complex (a-KGDHc) has been demonstrated to generate reactive oxygen species (ROS) (1,2) and could be a major source of oxidative stress related to senescence/aging, ischemia -reperfusion or neurodegenerative diseases (2 -4) . a-KGDHc is not only a source but also one of the most sensitive targets of ROS in mitochondria (5 -7) . Intrinsic radical species generated by a-KGDHc, which are intermediary products of the ROS-generating action of the enzyme, could contribute to the inhibition of a-KGDHc itself at the E1 subunit (8) ; hypoxia-and glutamate-induced cerebral damage was strongly linked to the inactivation of a-KGDHc by its own radical species generation (9) .
ROS generation by a-KGDHc was ascribed to the E 3 -subunit (lipoamide dehydrogenase, LADH, EC 1.8.1.4, also called dihydrolipoamide dehydrogenase, DLD) (1,2); isolated mitochondria from heterozygous E 3 knock-out mice produce significantly less ROS (2) . The E 3 subunit is shared with the pyruvate dehydrogenase complex (PDHc), the branched-chain keto-acid dehydrogenase complex (BCKDHc) and the glycine cleavage system (GCS) (10) ; the reason for a dominant role in ROS generation of a-KGDHc among these complexes is still unclear (11) . ROS production by LADH and a-KGDHc is potentiated by low pH (pH 6.3 -7.0) (12) , relevant to ischemia/reperfusion, and by Zn 2+ , which is found at elevated concentrations in ischemia/ reperfusion and Alzheimer's disease (13) .
When working in the physiologically relevant direction, LADH oxidizes the dihydrolipoic moiety bound as a prosthetic group to E 2 of a-KGDHc and generates NADH from NAD + (forward reaction). When the reverse reaction of E 3 is modeled in vitro, the isolated E 3 component oxidizes NADH while reducing model substrates, like lipoic acid or lipoamide (reverse reaction). When the electron-acceptor substrate (NAD + or lipoic acid/lipoamide) is scarce but O 2 is present, O 2 is reduced to superoxide anion, in either direction of the reaction, which is then dismutated to H 2 O 2 (ROS generation). LADH can also act as a diaphorase, reducing various organic molecules via the transfer of a single electron (14, 15) . LADH is capable of reducing not only O 2 or organic dyes, but also Fe 3+ or ubiquinone, suggesting a possible antioxidant role of this activity.
The LADH protein is a functional homodimer requiring amino acids from both monomers for its catalytic function (16) . Monomerization of the intact E 3 component has been demonstrated by various approaches (10, (17) (18) (19) (20) and was suggested resulting in the transformation of its physiological function to diaphorase (20) and Ser-protease activities (21) . Augmentation of diaphorase activity of LADH upon acidification was also suggested to be the result of monomerization of the LADH homodimer (20) ; however, no monomerization was detected in a study addressing the pH-dependence of the oligomerization state of LADH (12) . In this latter study, it was proposed that specific conformational changes in the LADH homodimer might lead to a shift in substrate preference at lower pH, which in turn could account for the switch in enzymatic function and for an increase in ROS generation.
Pathogenic mutations of the gene (Dld) encoding the human E 3 subunit of a-KGDHc have been identified and shown to result in E 3 -deficiency, an often lethal inherited genetic disease (22) (23) (24) (25) (26) (27) (28) (29) (30) . The crystal structure of human E 3 showed that disease-causing mutations involve three locations of the enzyme (16) : (i) the cofactor-binding sites (I12T, K37E, G194C, M326V, I358T), (ii) the disulfide redox center (active center) (P453L) or (iii) the dimerization surface (E340K, D444V, R460G) (16, 22) .
In the present study, we expressed and purified the most important pathogenic mutants of human LADH and determined their catalytic activities in the forward and reverse reactions to establish the functional loss associated with particular mutations. We also addressed the ROS-generating activity of the mutants to elucidate whether mutations could result in the augmentation of the ROS-forming ability. We demonstrate here a highly elevated ROS generation facilitated by four of the disease-causing mutations of the E 3 subunit studied here, a novel feature which might significantly contribute to the clinical presentation of E 3 -deficiencies and could be a target in the treatment of the disease.
RESULTS

Specific activities of LADH mutants
LADH mutants were expressed with an eight-amino acid long N-terminal Strep-affinity tag and directed to the periplasm of E. coli, from where they were isolated and purified. In addition to the disease-causing mutations, we also studied the L174F mutation identified on the mRNA level in human brain (EMBL#:AB209703) and the S456A, E431A and D444V/ S456A mutants which abolish (S456A, E431A) or partially restore (D444V/S456A) the Ser-protease activity of LADH (21) . Protein products were found intact and highly pure after purification (Supplementary Material, Fig. S1 ). Mutations were confirmed for all mutants by limited proteolysis and tandem mass spectrometry (MS) using proteases GluC, trypsin and AspN (data not shown).
The precise determination of protein concentrations was essential in this study. To avoid interference of flavin adenine dinucleotide (FAD) in the photometric assay, we used the Bradford method to determine protein concentrations; correlation coefficients R 2 ≥ 0.973 were calculated for calibration curves in each Bradford assay.
Kinetic parameters of wt-LADH were similar to those published earlier including the ping-pong bi-bi mechanism (13,15,31 -33) 21 were found, as measured in the reverse reaction.
Catalytic activities of the LADH mutants under identical conditions were tested in a single experiment using a multititer-plate assay (Fig. 1 ). This allowed, for the first time, a direct comparison of the degree of functional loss exhibited by the different disease-causing LADH mutations under controlled conditions. The specific activity of the wt-LADH in the forward reaction was found to be 2.81 + 0.09 mmol NADH/min/mg (n ¼ 5). As demonstrated in Figure 1A , all the mutants except G194C and L174F presented with a reduced specific activity relative to that of wt-LADH. The degree of the reduction in the catalytic activity was variable among the mutants; two of them, M326V and P453L, showed near-complete loss of activity. The specific activity of wt-LADH in the reverse reaction was 161.79 + 7.82 mmol NADH/min/mg (n ¼ 3) and the pattern of changes obtained with the mutants was essentially similar, i.e. loss of function in case of the majority of the mutants, but for a few notable exceptions (Fig. 1B) in which the changes in the forward and reverse rates were dissimilar. The K37E mutant exhibited a reduced activity in the forward reaction (70 + 4%, n ¼ 5), but a higher specific activity in the reverse reaction (126 + 4%, n ¼ 5). The L174F mutant selectively increased the reverse activity (131 + 4%, n ¼ 5), while the D444V/S456A double-mutation selectively reduced the forward activity (26 + 5%, n ¼ 5), but neither of them affected the activity in the opposite direction.
The quantitative data obtained here using the purified proteins are difficult to compare to available literature data for a number of reasons: (i) the majority of data available so far were derived from measurements of LADH activity in tissue samples from patients suffering from E 3 -deficiency, where the enzyme activity might be influenced by tissue conditions which are not, or only indirectly, related to a particular mutation (22) (23) (24) (25) (26) (27) (28) (29) (30) , (ii) patients providing tissue samples for LADH measurements are often compound heterozygotes bearing a second mutation in the Dld gene (24, 25, 27, 29, 34) , (iii) measurements from tissue samples have been inconsistent in different studies as to addressing LADH activity in the forward (22, 24, 26) or the reverse reaction (23, 29) . In spite Human Molecular Genetics, 2011, Vol. 20, No. 15 2985 of these ambiguities, our results are in concord with most of those in the literature, demonstrating a reduced activity of the mutant LADH enzymes. However, it is important to note that with the welldocumented pathogenic mutation G194C, we found no change either in the forward or the reverse reaction using the purified protein. This is in contrast to the invariably reduced LADH activity found in muscle samples and lymphocytes (29) or skin fibroblasts (26) from patients with lipoamide dehydrogenase deficiency due to the G194C mutation.
ROS generation by LADH mutants
ROS generation by the LADH mutants was measured by two independent methods, detecting superoxide using the acetylated cyt c reduction assay or H 2 O 2 using the Amplex Red fluorescence assay. The primary ROS product generated by LADH is superoxide, which readily dismutates to H 2 O 2 and O 2 (8, 35) . The rate of ROS production by four pathogenic LADH mutants, D444V (aspartate to valine), E340K (glutamate to lysine), P453L (proline to leucine), G194C (glycine to cysteine) and the double-mutant D444V/S456A (aspartate to valine/serine to alanine) (see also Supplementary Material, Fig. S2 ) was significantly increased when compared with that measured with wt-LADH (Fig. 2) . The rate of ROS generation by the other mutants was generally reduced relative to the wild-type (WT), although the degree of reduction was variable. 
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To confirm the above results, mutants showing elevated ROS production except D444V/S456A, which is not a real pathogenic mutation, plus a new batch of wt-LADH were expressed and purified again. Protein products were again subjected to sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS -PAGE) analysis (Supplementary Material, Fig. S1 ) and tandem MS analysis. ROS production was tested for the new preparations by the cyt c assay and showed similar results as for the first preparations, but the increases relative to wt-LADH were slightly different: G194C: 171 + 4%, n ¼ 3; E340K: 153 + 0%, n ¼ 3; D444V: 188 + 2%, n ¼ 3 and P453L: 254 + 4%, n ¼ 3.
The results of the cyt c assay were verified by measuring the rate of H 2 O 2 generation by the disease-causing LADH mutants which presented with elevated superoxide production (Fig. 3) ; in this experiment, the pH-dependence of H 2 O 2 generation by the mutants was also addressed. As acidosis is often found among the clinical phenotypes of E 3 -deficiency, it is relevant to establish whether stimulation of ROS generation by the mutations is sensitive to changes in pH. The pH dependence of LADH activity in its reverse (20) and ROS-generating reactions (12) has already been characterized for the WT enzyme. Figure 3 demonstrates that H 2 O 2 generation by wt-LADH increased from 0.513 + 0.005 mmol/min/mg (n ¼ 3) observed at pH 7.3 to 1.58 + 0.17 mmol/min/mg (n ¼ 3) when measured at pH 6.3. This approximately 3-fold increase in the rate of H 2 O 2 production at pH 6.3 was also observed with the mutants, indicating that the already higher ROSforming capacity detected at pH 7.3 could be further increased at this acidic pH. It is even more remarkable that at pH 6.8, where the rate of H 2 O 2 generation by wt-LADH (0.606 + 0.041 mmol/min/mg, n ¼ 3) was not significantly different from that observed at pH 7.3, three mutants (D444V, E340K and P453L) produced H 2 O 2 at significantly higher rates. The rates of H 2 O 2 generation (in mmol/min/mg) at these two pH values were 2.054
. This clearly shows increased sensitivity of ROS generation by these mutants to an acidic shift in pH.
Lack of correlation between FAD content or protein conformation and ROS generation by the LADH mutants
We attempted to correlate the changes in specific activities and ROS generation to various biophysical factors, including FAD content, protein conformation and monomerization of the LADH proteins.
FAD content was measured for wt-LADH and for mutants showing elevated ROS production (P453L, G194C, E340K, D444V), plus for K37E, which is known to affect FAD binding (36) . Similarly to previous reports (17, 31, 32) , we found that 1 mol wt-LADH monomer binds 1 mol FAD (1.01 + 0.017). FAD binding of E340K and D444V was similar to that of wt-LADH (0.99 + 0.027 and 0.95 + 0.024 FAD/LADH monomer, respectively), while it was decreased in P453L, G194C and K37E (0.66 + 0.047, 0.72 + 0.011 and 0.67 + 0.048 FAD/LADH monomer, respectively). The value obtained here for K37E is similar to that (0.76) measured earlier (36) . The far-UV circular dichroism (CD) spectral signature (195 -240 nm) of wt-LADH was found to be similar to the porcine equivalent (.95% sequence homology to human) (37) , and also to those from other species (38) . When we carried out folding analysis of LADH mutants by CD spectroscopy, we found no relevant changes in the spectral signatures in any of the cases (Fig. 4 and Supplementary Material, Fig. S3 ), suggesting that the applied mutations had not triggered radical conformational changes that could directly be correlated to the decreased specific activities or the enhanced ROS generation by the LADH mutants. Small changes in CD signature were found for a few mutants (Fig. 4) ; spectral signatures of all the rest of the mutants presented nearly no change at all (Supplementary Material, Fig. S3 ). Only one of the mutants which exhibited elevated ROS generation, G194C, caused detectable changes in CD (Fig. 4) .
Oligomerization order of LADH mutants
Mutations of the dimerization surface of LADH (D444V, E340K and R460G) have been proposed to affect the stability of the functional homodimer (16, 30) and to enhance the Ser-protease activity of LADH (21), while monomerization was shown to favor the diaphorase activity of the enzyme (20) . Calibrated size-exclusion chromatography was previously used to demonstrate that lowering the pH did not result in the monomerization of wt-LADH (12), contrary to previous suggestions (20) . Figure 5A shows the size-exclusion chromatography elution profiles of the dimerization surface mutants and that of P453L, when compared with the one of wt-LADH at pH ¼ 6.80. P453L was included here as a clearly different mutation, in which the mutation is in the active center and not at the dimerization surface. The elution profiles unambiguously indicate that these proteins eluted from the column with similar elution volumes, distinct from that expected for monomeric LADH protein ( 50 kDa). Plotting log(MW) against V e /V o , we found, as expected, a linear dependence for calibration proteins, while all LADH variants, including wt-LADH, were located in the region that represents a dimeric LADH protein. R460G and D444V proteins were also eluted in negligible amounts in the monomer region, a finding consistent with the minute increase in the proteolytic activity found with D444V (21) .
To verify the above findings, we subjected proteins eluted in the gel filtration experiment directly to soft-ionizing nano-LC MS and examined the oligomerization order also by this technique (Supplementary Material, Fig. S4 ). Mass spectra for wt-LADH, E340K, D444V and P453L showed peaks only in the upper mass region indicating that the measured proteins were in their dimeric forms: deconvolution of spectra showed MWs of 105 kDa in each case. For R460G, signals could only be detected at pH ¼ 2, where, in the MS source, most non-covalent oligomers monomerize (39) . Undetectable m/z ratios to our instrumentation at pH ¼ 6.8 were probably due to lower charge states, potentially caused also by the Arg to Gly mutation. Signal appearance upon acidification confirmed the dimeric molecular weight also for R460G.
These results are unexpected as they indicate a lack of monomerization due to mutations which involve the dimerization surface of LADH. It is also clear that monomerization could not be an underlying structural change in the enzyme explaining either the decreased catalytic activities or the enhanced ROS-generating activities of the mutants.
DISCUSSION
Pathogenic mutations of LADH, the E 3 subunit of a-KGDHc, PDHc, BCKDHc and GCS, result in the inherited, often lethal metabolic disease called E 3 -deficiency. Here we expressed, purified and investigated the most important pathogenic mutants of LADH reported in the literature and demonstrated that four mutations (G194C, P453L, E340K and D444V) significantly enhance the ability of LADH to generate ROS. These mutations also increase the sensitivity of ROSgenerating activity of LADH to an acidic shift in pH. This newly found feature of LADH mutations could significantly contribute to the pathology of E 3 -deficiency and raises the 
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Human Molecular Genetics, 2011, Vol. 20, No. 15 possibility of the beneficial use of antioxidants in the therapy of these diseases. The study on the specific activities of the purified mutants also enables the assessment and the comparison of the functional consequences of particular mutations. Below, our discussion is focused mainly on results obtained with those mutations which stimulated ROS generation by the enzyme. The location of the mutation in E 3 has no obvious relation to the stimulation of ROS generation. Among the mutations that facilitated ROS generation, two are at the homodimer interface (E340K, D444V), one at the disulfide-exchange site (P453L) and one at the FAD/pyridine-nucleotide binding site (G194C); however, other mutations at the same locations failed to affect ROS generation.
No evident relationship was found between the conformational change induced by the mutation and the enhanced ROS-generating capacity of LADH. Some of the mutations studied here caused moderate conformational changes, but among the mutants showing elevated ROS production only the G194C mutation caused evident conformational changes according to CD. It is possible that the accessibility of the electron-transfer sites to O 2 is altered in particular mutant LADH molecules, but to establish this, the atomic level structures should be determined by X-ray crystallography. The correct assembly of the functional LADH homodimer is a prerequisite for LADH activity, as amino acids from both monomers are involved in the catalytic action (16) . Previous studies demonstrated monomerization of wt-LADH only under extreme conditions [chemical modification, freeze-thawing, extreme dilution, high salt or acidity, in the presence of denaturants or by apomerization (10, 14, 15, (17) (18) (19) (20) or recently in reverse micelles in organic solvents (20) ]. A study reporting that the Ser-protease catalytic dyad is at the dimerization surface could show only very limited enhancement in proteolytic activity, and no appearance of a distinct monomeric peak during gel filtration, of the D444V protein (21) . Our results showing a lack of monomerization with the D444V mutation [as well as with others for which the mutation was identified to be at the dimerization surface (E340K, R460G)] are in concordance with this finding. These somewhat unexpected findings could initiate further studies on the possible mechanism(s) other than monomerization underlying the functional loss caused by these mutations.
The reduced enzyme activity directly related to a particular mutation was revealed by comparing the specific activities of LADH mutants in the forward and reverse reactions. Generally, the majority of the mutants showed reduced activity (to various extents) in both directions, but there were a few exceptions: the decrease in the forward reaction paralleled an increase or no change in the reverse activity for the K37E and D444V/S456A proteins, respectively, and in the case of L174F the reverse activity was enhanced without an alteration in the forward reaction. Importantly, the G194C mutation did not cause any alteration in the specific activity of LADH in either direction.
No consistent pattern was apparent in the specific activities of those mutants that exhibit an enhanced rate of ROS generation (Table 1) . Nevertheless, the ratio of ROS-generating activity to the physiological LADH activity, shown in Table 1 , clearly indicates that due to these mutations the enzyme gains ROS-forming activity over the normal catalytic function. The highest ROS-forming activity is gained due to the P453L mutation, which results in a drastic loss of the physiological activity (9% of the WT) and a quite remarkable increase in the ROS-forming activity. In fact, we detected the highest rate of ROS generation with this mutant. This mutation takes place in the active center of LADH where P453 is adjacent to H452, a catalytic residue; the peptide linkage with P453 in its place favors cis conformation and the peptide carbonyl is then H-bonded to the N3 of FAD. To explain the loss of catalytic activity in the P453L mutant, it was suggested that Leu in place of Pro does not prefer a peptide bond in cis conformation, which leads to local derangement of even main-chain atoms, concomitant misplacement of the H452 side-chain and disruption of the linkage to FAD (16) . In agreement with this hypothesis, P453L showed a 33% decrease in FAD binding in our hands. When expressed in yeast, the P453L protein lost its enzyme activity completely (40) . The mechanism by which the ROS-forming capacity of this mutant increases is unclear, but it appears that this mutation turns LADH largely into a ROS-producing enzyme. The clinical manifestation of this mutation is very severe (27, 41) as reported for a compound heterozygote patient identified to carry a P453L/K37E double mutation [K37E is a much less destructive mutation, see Fig. 1 in this study and other references (36, 40, 42) ]. The drastic rise in ROS generation due to the P453L mutation suggests that the severe clinical phenotype associated with this mutation may not be simply due to loss of E 3 function; concomitant excessive ROS generation could also contribute to overall disease pathology.
The moonlighting proteolytic activity of LADH was found enhanced by the D444V mutation, even when the proteolytic activity was almost completely diminished by the S456A and the E431A alanine-replacement mutations (in the S456A/D444V double mutant) (21) . Both D444V and S456A/D444V mutations similarly decreased the specific activity of LADH in the forward reaction, but interestingly, the activity in the reverse reaction was preserved in the double mutant but not in D444V. Apparently, this is unrelated to ROS generation, which was significantly enhanced by both mutations (to 130% of the WT activity). LADH activity was decreased in muscle homogenates from both homozygous and heterozygous patients carrying the D444V mutation and the clinical phenotype involved severe metabolic acidosis (30) . Given our data that this mutation not only increases ROS generation but also renders ROS generation more sensitive to an acidic shift in pH, it appears likely that oxidative stress could be a contributing factor in the clinical presentation of the D444V mutation. A relatively small reduction in LADH activity was found with the E340K mutation (to 64 + 4 and 71 + 5% in the forward and reverse reaction, respectively) indicating that this primary defect in the DNA does not result in a complete loss of LADH activity. No information on the purified enzyme is available in the literature, therefore our data can be compared only to clinical data from patients carrying the E340K mutation in combination with a second mutation (22, 25, 34) . These data revealed a significantly higher loss of LADH activity than our study and a complete loss of a-KGDHc activity (22, 25) . It is possible that the functional consequences of this mutation in vivo reflect the effect of oxidative stress due to elevated ROS generation by this mutant.
The G194C mutation was the only one addressed in this study, which did not cause any alteration in the specific activity of LADH, but did enhance significantly the ROSgenerating activity of the enzyme. This mutation is associated with an E 3 -deficiency common among Ashkenazi Jews [with a carrier rate of 1:100 (29)]. LADH activity was decreased in muscle samples from patients homozygous for this mutation (26, 29) , and also for compound heterozygotes (22, 29) . It is remarkable that the purified mutated protein, examined for the first time in our study, functioned with similar activity to the WT enzyme. This indicates that the reduced enzyme activity found in patients is unlikely a direct consequence of the G194C mutation itself, but may be due to other factors associated with the disease. It was also noted (22) that E 3 activity per se is not a major determinant of the clinical severity of the disease. The highly elevated ROS generation found in our study could be of great importance and suggests that oxidative stress in mitochondria associated with this mutation might contribute to inhibition of E 3 -containing enzymes in these patients (29) , in particular to that of a-KGDHc (22), and to the clinical phenotype of this mutation. Metabolic acidosis could further stimulate ROS generation in these patients, since the highest increase in ROS generation at low pH was associated with this mutation.
L174F, a brain-specific mutation, showed no difference relative to wt-LADH in the forward reaction and in ROS generation, but showed a 30% increase in activity in the reverse reaction; the results suggest no significant tissue-specific difference in enzymatic action.
Another interesting mutation was M326V, which presented with severe decline in forward, reverse and ROS-generating activities, suggesting that the catalytic apparatus is fully compromised [in concert with previous results (34) ].
In summary, we suggest that enhanced ROS-forming activity of LADH due to certain mutations could be a critical factor in the clinical manifestation of E 3 -deficiencies. Oxidative stress likely generated by the mutant enzymes in vivo could impair the function of a number of proteins including those working with the mutant E 3 subunit. Future studies will have to address the fine structural changes in the proteins responsible for the enhanced ROS generation. The novel information from this work concerning the enhanced ROSgenerating capacity of LADH mutants might initiate an antioxidant therapy for patients suffering from E 3 -deficiency.
MATERIALS AND METHODS
Chemicals
All chemicals were purchased from Sigma (St Louis, MO, USA) if not stated otherwise. All buffer components were obtained as molecular biology grade chemicals lacking protease activities. pH of buffers was adjusted by concentrated HCl or KOH for all experiments. Racemic mixtures (R, S) of both dihydrolipoic acid (DHLA) and lipoamide (LAM) were used after dissolution in dimethyl sulfoxide (Me 2 SO; 1 M stock solution); for LAM, 10 min incubation at 408C with vigorous agitation was necessary for complete dissolution. Me 2 SO was of UV spectroscopy grade. LAM, DHLA, NAD + , NADH and cyt c stock solutions were always prepared fresh and stored protected from light, in case of NAD + , NADH and cyt c on ice, until used.
Plasmid construction and DNA manipulations
The WT plasmid was generated for previous studies using standard cloning techniques as previously described (43); cDNA for human Dld was obtained from Origene Technologies, Inc. (Rockville, MD, USA), the target expression vector plasmid pASK-IBA6C was purchased from IBA (Gottingen, Germany) while the expression host JM83, for periplasmic expression (43) , was from LGC Promochem GmbH (Wesel, Germany). pASK-IBA6C works with chloramphenicol resistance containing sequences for an ompA targeting signal to the periplasm and a Strep-affinity tag for affinity purification after the promoter upstream of the Dld cDNA which lacked the 35aa mitochondrial signal peptide; the gene of interest was inserted between BsaI cleavage sites. Single and double point mutations were introduced by the QuikChange II Site Directed Mutagenesis Kit (Stratagene; Cedar Creek, TX, USA) according to the manufacturer's specifications. Primers for the designated point mutations were designed by the QuikChange Primer Design program and purchased from IBA as HPLC purified oligonucleotides. Sequences for the applied DNA oligonucleotide primers are collected in Supplementary Material, Table S1 . Clones, whether they bore the required mutations in the correct positions, were confirmed by DNA sequencing (Agowa GmbH, Berlin, Germany). DNA constructs were sequenced in a way that the forward and the reverse sequencing reactions always overlapped verifying both the sites of the mutations and the correctness of the full gene of interest.
Protein expression and purification
Protein expression and purification has been performed for all mutants as for wt-LADH (43) . Briefly, freshly transformed JM83 single colonies were used in overnight cultures [LB medium with 30 mg/ml chloramphenicol (LB-CL), 200 rpm, 128C] which were added to fresh LB-CL for inoculation in a 1:50 volumetric ratio. Protein expression was induced by 200 ng/ml (final concentration) anhydrotetracycline (IBA) at OD 0.6 and was allowed to proceed for 24 h. Cells were harvested at 4500g, 48C for 12 min. Strep-tagged proteins were released from the periplasm of E. coli by resuspending bacterial pellet in 1 ml of buffer A (100 mM Tris, 500 mM Macroprep FPLC columns (IBA) were used. For FPLC purification, an AKTA Purifier 10 UPC FPLC system (GE Healthcare Biosciences AB, Uppsala, Sweden) was applied with 3 ml/min flow rate and the following protocol at 48C: after equilibration with buffer B (100 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 8.0) and sample administration, proteins bound non-specifically were washed off with five column volumes (CV) of buffer B and finally Strep-LADH proteins were eluted in one step by three CV of buffer C [buffer B + 2.5 mM desthiobiotin (IBA)]. Columns were regenerated according to the manufacturer's specifications. Protein eluates were buffer-exchanged to 50 mM K-PO 4 , pH 7.3 using Amicon Ultracel centrifugal filtering tubes (MWCO ¼ 30 kDa; Millipore, Cork, Ireland) at 48C, concentrated, aliquoted, fast-frozen in liquid N 2 and stored at 2808C, until use. The S456A mutant precipitated at higher protein concentrations; hence, only its 0.7 mM (monomeric concentration) solution could be used for all analyses.
SDS -PAGE analysis
Samples were subjected to SDS -PAGE analysis for determining molecular weight, purity and integrity as described before (43, 44) . Briefly, for gel electrophoresis, NuPAGE Novex Bis -Tris precast gels with 10 or 12 wells, and related chemicals, were used from Invitrogen. Twenty or 10 ml volumes of samples or MW markers [Rainbow MW marker (GE Healthcare, Buckinghamshire, UK) or SigmaMarker wide range (Sigma)], respectively, were loaded on gels. Sample preparation, the electrophoresis experiment and staining of the gel by SimplyBlue SafeStain (Invitrogen) followed the manufacturer's specifications.
Mass spectrometry
Identification of mutations was performed using the 'bottom-up' proteomic method similarly to references (43, 44) . For limited proteolysis of mutated LADH proteins, the following proteases were applied: trypsin (from porcine pancreas, proteomics grade), endoproteinase Glu-C (from Staphylococcus aureus V8) and Asp-N (from Pseudomonas fragi mutant strain). Digestion trials were carried out by the three different proteases for all LADH mutants, and the best performing combination was selected for the final analysis. For protein denaturation, the RapiGest SF denaturant (Waters, Milford, MA, USA) was used; this surfactant is compatible to protein digestions with trypsin, Glu-C or Asp-N and subsequent HPLC-MS analysis. 'In solution' or 'in gel' digestion procedures were used, depending on sample. During 'in solution' digestion, proteins were first treated with DTT at 608C for 30 min in the presence of RapiGest SF followed by the addition of 100 mM NH 4 HCO 3 until pH ¼ 7.8 was reached. For cysteine alkylation, iodoacetamide (IAA) was used for 30 min in dark at room temperature. Proteolytic digestion was carried out at 378C for 1.5 h for trypsin or overnight for others. Digestion was ceased by adding 1 ml of 500 mM formic acid (HCOOH) and then samples were further incubated for 30 min at 378C for RapiGest SF to hydrolyze. After spin-down centrifugation, samples were subjected to MS. During 'in gel' digestion, gel spots were carefully excised and sliced to 1 mm pieces. Gel pieces were repeatedly washed with ddH 2 O, acetonitrile (ACN), 100 mM NH 4 HCO 3 and ACN in this sequence before drying by speedvac for 30 min. Gel pieces were further incubated in 5 ml of 200 mM DTT/45 ml of 100 mM NH 4 HCO 3 for 30 min at 608C. After centrifugation and removing the supernatant, gel pieces were incubated in 8 ml of 100 mM IAA/22 ml of 100 mM NH 4 HCO 3 for 30 min in dark. Next, the supernatant was removed and samples were repeatedly washed with ACN, 100 mM NH 4 HCO 3 and ACN in this sequence. After centrifugation and removing supernatant, samples were dried by speed-vac for 30 min. Subsequently, 20 ml of 0.2% RapiGest SF in 100 mM NH 4 HCO 3 was added to samples and they were left incubating at 378C for 10 min. Excess solution was removed and gel pieces were left to completely dry. As a next step, 50 ml of 1 mM protease in 100 mM NH 4 HCO 3 was added to samples and incubation was carried out on ice for 45 min. After removing excess solution, 35 ml of 100 mM NH 4 HCO 3 was given and the mixture was incubated at 378C overnight. Five microliter of 500 mM HCOOH was used to cease reaction. The resulting peptides were eluted from gel by repeated incubation with 15 ml of 5% HCOOH/50% ACN/45% ddH 2 O. After each step, samples were centrifuged and the supernatants were collected. LC-MS(MS) analyses of resultant peptide mixtures were performed on a Waters Q-TOF Premier mass spectrometer coupled to a nanoAcquity UPLC (Waters) for which a 75 mm × 150 mm BEH300 C 18 capillary column was used with a 1.7 mm particle size. LC-MS-grade water with 0.1% HCOOH and ACN with 0.1% HCOOH were used as eluent A and B, respectively, and a gradient from 10 to 40% B in 70 min was applied using these solutions with a 400 nl/min flow rate. . Experiments were carried out in a single 50 ml Suprasil quartz cuvette (Hellma, Jena, Germany). FAD concentrations of WT and mutant holoenzyme stock solutions were measured in three replicates after 5 min boiling in water bath and centrifugation at 48C and 15 000g for 5 min to remove protein; 1 455 nm (see above) determined under the above conditions (after boiling) using free and oxidized FAD in 50 mM K-PO 4 (15) . Determinations by the Bradford method were carried out according to the instructions accompanied the Bradford reagent from Sigma, utilizing a Victor 3 multilabel counter spectrophotometer/fluorimeter (Perkin Elmer, Waltham, MA, USA). Five microliter of bovine serum albumin reference or protein sample was mixed to 250 ml Bradford reagent, agitated on a laboratory shaker for 30 s and left incubating for 10 min at ambient temperature before measurement; we applied five parallel experiments for samples and references and from the latter well-correlating (R 2 . 0.973 always) seven-point linear reference curves were constructed ranging from 0.1 to 1.4 mg/ml.
Measurement of specific activities
Specific activity of LADH in the reverse reaction was measured similarly to established protocols (10, 13, 32) : the initial rate of NADH consumption was measured at 340 nm in EIA/RIA 96-well, flat-bottom, polystyrene plates (Corning, Lowell, MA, USA) using a Victor 3 multilabel counter spectrophotometer/fluorimeter at 378C. Due to the competitive inhibition of Pi toward NAD + and the inhibition by NADH as a product (competitive at high concentrations, non-competitive near the Michaelis constant) and as a substrate (non-competitive, becoming severe beyond 200 mM), optimal 50 mM Pi and 165 mM pyridine-nucleotide (NAD + , NADH) concentrations were used in all measurements (12, 33, 47) . For each experiment, a 300 ml final reaction volume in 50 mM K-PO 4 , pH 7.3 was used containing 165 mM NADH and 0.9 mM lipoamide (LAM) in final concentrations and 12.3 ng protein (same amount for all mutants and wt-LADH); K M (NADH) ¼ 8.7 mM for porcine LADH, .95% homology to human (48) ; K M (LAM) ¼ 1.33 mM for LADH isolated from human liver (32) or 0.56 mM for the recombinant enzyme (31); LAM has poor solubility in H 2 O, higher than 1 mM LAM precipitates in the applied buffer. Reactions were initiated by the addition of NADH after 15 min incubation at 378C; the volume of the added NADH solution, which was kept on ice until use, was ,2% of the total reaction volume to avoid temperature anomalies. Specific activities in the forward reaction were measured under the same experimental conditions as above, including reactant concentrations, except that the amount of protein was 123 ng (for better sensitivity) and that NAD + , instead of NADH, and DHLA instead of LAM, were used. Here reactions were initiated by the addition of DHLA. The volume of added Me 2 SO to reaction mixtures was always exactly 1%. NADH absorbance was measured at the beginning of each experiment. Only NADH solutions in which the absorbance corresponded to at least 85% of the expected absorbance (calculated from the molar extinction coefficient) were used.
Enzyme mechanism
The ping-pong bi -bi mechanism and related constants (K M and V max ) of the wt-LADH enzyme were examined and analyzed in the reverse reaction, similarly to previous studies (33) . Initial reaction velocities at five NADH concentrations (10 -100 mM) and five LAM concentrations (0.2 -0.9 mM) in the presence of 12.3 ng protein were measured. All experimental conditions were the same as for measuring specific activities in the reverse reaction. For analysis of experimental data, the Florini -Vestling method (50) was used which is a double-reciprocal linearization method for two-substrate enzyme reactions described by Eq. (1) (see below); in this method, double-reciprocal plotting of Eq. (1) must be performed twice, first against the reciprocal concentration of one of the substrates, then against that of the other substrate to gain all the three required kinetic constants (K M for NADH and LAM, and V max ).
The least-squared fitted lines to data points of the primary plot for wt-LADH were close to parallel representing a ping-pong mechanism (data not shown); sequential mechanism would require lines to cross in the second quarter of the coordinate system in this model. Results are averages of five repetitions.
Measurement of superoxide generation
Superoxide generation by LADH mutants was measured by reduction of acetylated cytochrome c (cyt c) as described before (51) . Initial reaction velocity was measured and converted to generated superoxide amount per unit time for 1 mg protein taking into account that the stoichiometry of the reaction between cyt c and superoxide is 1:1 (51). Solution conditions were the following in a 200 ml final reaction volume: 50 mM K-PO 4 , pH ¼ 6.3, 50 mM acetylated cyt c, 165 mM NADH, 2.468 mg protein (all measured mutants); concentration of cyt c was chosen to determine a linear dynamic range for measurement by a 10 nm bandwidth optical filter. Measurements were carried out at 378C at the absorbance maximum of 550 nm of the reduced form of acetylated cyt c in EIA/RIA 96-well, flat-bottom, polystyrene plates using a Victor 3 multilabel counter spectrophotometer/fluorimeter. The reaction was initiated by the addition of NADH after 15 min incubation at 378C; the volume of added NADH solution was 1.6%. Extinction coefficient of the reduced acetylated cyt c was determined by fully reducing oxidized cyt c under the assay conditions by sodium dithionite; a . Superoxide dismutase from bovine erythrocytes (SOD) was used to verify that the cyt c reduction was indeed caused by superoxide generated by LADH enzymes; 100 U SOD were given to 200 ml of reaction mixture, where applied.
Measurement of H 2 O 2 generation
To detect H 2 O 2 generated by LADH mutants, the Amplex Red fluorescent dye (Molecular Probes, Eugene, OR, USA) (52) was applied as detailed before (1, 12) . In the presence of horseradish peroxidase (HRP), the Amplex Red reagent reacts with H 2 O 2 with a 1:1 stoichiometry producing highly fluorescent resorufin. Fluorescence was detected in a PTI Deltascan fluorescence spectrophotometer (Photon Technology International, PTI, Lawrenceville, NJ, USA) using 550/585 nm excitation/ emission wavelengths. A calibration signal was generated with known quantities of H 2 O 2 at the end of each experiment; this is how the effect of pH on the Amplex Red + HRP detection system was also been taken into account. Reactions were initiated by the addition of enzymes after a 15 min preincubation at 378C of Amplex Red and HRP in buffer and the stabilization of the fluorescent signal, generally 200 s after the addition of NADH at 100 s. For calculation, the slope of the curve in the presence of only NADH + Amplex Red + HRP was subtracted from the initial slope detected in the presence of LADH. Conditions: 165 mM NADH, 10 nM (monomeric concentration) protein (1.04 mg), 1 U HRP, 1 mM Amplex Red, 50 mM K-PO 4 , pH ¼ 6.3-7.3, 378C in a 2 ml final reaction volume, which was continuously stirred.
CD spectroscopy
CD signatures of the WT and mutant proteins were recorded on a Jasco J-720 spectropolarimeter (Jasco, Easton, MD, USA). A quartz cell of 0.5 mm optical path length and an instrument scanning speed of 50 nm/min, with 2 s response time, were used for measurements, and data presented in figures were averages of at least five repetitions. Wavelengths were scanned between 195 and 250 nm; all experiments were carried out at ambient temperature. Baseline correction, subtraction of buffer signal and normalization were performed on each spectrum. Protein solutions were of 1 -5 mM (monomeric) in 50 mM K-PO 4 , pH 7.3.
Size-exclusion chromatography
Experiments were carried out at 48C on an AKTA Purifier 10 UPC FPLC system using a HiPrep 16/60 Sephacryl S-200 HR gel-filtration column applying a 0.5 ml/min flow rate (12, 53) . Sample volumes, always 300 ml, were loaded to column from a 1 ml loop. The running buffer was 150 mM ammonium acetate (NH 4 Ac, LC-MS grade), pH ¼ 6.80 (no pH adjustment was necessary); as high as 150 mM concentration of NH 4 Ac was applied to avoid unspecific binding to the chromatographic matrix. For molecular weight calibration, the Gel Filtration MW Marker kit from Sigma was used; calibration proteins and their MWs can be seen in Figure 5 . Stock solutions for calibration proteins were prepared at concentrations recommended by the kit in 50 mM K-PO 4 , pH ¼ 7.3. Samples loaded for calibrating proteins contained 100 ml of the above stock solutions mixed with 200 ml of running buffer. For wt-LADH and mutants, 300 ml of 1-3 mM samples in 50 mM K-PO 4 , pH ¼ 7.3 were loaded without further dilution. Peaks for wt-LADH and mutants were collected and concentrated by Amicon Ultracel cells (MWCO ¼ 30 kDa) to 100 ml and subjected to nano-LC-MS. Elution was left running long after the elution of the peaks to investigate the presence of potential smaller components.
Nano-LC MS
For non-covalent interaction MS, purified LADH proteins eluted from the FPLC gel filtration column (see above) were used in 3 -10 mM protein concentrations in 150 mM NH 4 Ac, pH ¼ 6.8; before each measurement, HCOOH was added to samples in a 0.05% final concentration. Measurements were performed using a Waters Q-TOF Premier mass spectrometer equipped with a nano-flow electrospray source. Samples were infused directly using a syringe pump with a 0.8 ml/min flow rate. Capillary and cone voltages, 2.3 kV and 15 V, respectively, and collision energy of 5 V were found optimal for minimal fragmentation of the LADH homodimers. The ion guide gas inlet flow rate was set to 5 ml/min on the mass spectrometer. Spectra were acquired between 2000 and 6000 m/z.
Molecular modeling
Molecular representations were made using Pymol (www.pym ol.org, last accessed: May 09, 2011) and were further rendered in POV-Ray (www.povray.org, last accessed: May 09, 2011).
Statistics
Statistical differences were evaluated in Excel with two-tailed Student's t-tests assuming unequal variances and were accepted to be significant when P , 0.05. the Bolyai Fellowship of the Hungarian Academy of Sciences (to A.A.).
